Bristol-Myers Squibb (BMY) has received positive news regarding its pipeline, including a Priority Review for Camzyos in adolescent obstructive hypert...
Bullish
Motley Fool Asset Management LLC increased its stake in Bristol Myers Squibb Company by 30.4% in the fourth quarter, acquiring an additional 50,403 sh...
Neutral
BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data from their ROSETTA Lung-02 clinical trial evaluating pumitamig plus chemo...
Neutral
Focus Partners Advisor Solutions LLC grew its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 88.0% in the fourth quarter, accord...
Bristol-Myers Squibb (BMY) stock closed down 3.00% on June 8, primarily due to concerns over generic competition impacting key drugs like Revlimid, Po...
Actress Mariska Hargitay has partnered with Bristol Myers Squibb (BMS) for an awareness campaign called "Investigating Myeloma," inspired by her fathe...
Actress Mariska Hargitay has teamed up with Bristol Myers Squibb to launch the "Investigating Myeloma" awareness campaign. Commemorating the 20th anni...
Bullish
Bristol Myers Squibb has initiated an awareness campaign called "Investigating Myeloma" in collaboration with actor Mariska Hargitay, whose father die...
Bullish
Mariska Hargitay has partnered with Bristol Myers Squibb (BMS) to launch "Investigating Myeloma," an awareness campaign dedicating to highlighting the...
Bullish
Mariska Hargitay is honoring her father, Mickey Hargitay, in a new Bristol Myers Squibb (BMS) awareness campaign called "Investigating Myeloma." Her f...
Neutral
PBU The Pension Fund of Early Childhood & Youth Educators acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the fou...
Neutral
Capital International Investors trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 35.2% in the fourth quarter, accordin...
Bullish
Bristol Myers Squibb and SystImmune have announced positive phase 3 results for izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjuga...
Bullish
Bristol Myers Squibb CEO Chris Boerner discussed the company's recent cancer drug data and its $15 billion deal with China's Hengrui Pharma at the Ame...
Bullish
Bristol-Myers Squibb reported a 1% year-over-year revenue increase to $11.5 billion for Q1 2026, with their Growth Portfolio growing 9%. The company h...
Bullish
Bristol-Myers Squibb (BMY) has announced a new Phase 2 trial for BMS-986504 (Navlimetostat), a targeted cancer drug for solid tumors with homozygous M...
Bullish
Bristol Myers Squibb announced positive Phase 3 results for its CELMoD mezigdomide, demonstrating a 52% reduction in the risk of disease progression o...
Bullish
Bristol Myers Squibb announced positive results from a late-stage trial for its multiple myeloma drug candidate, mezigdomide. When used as part of a c...
Bullish
Bristol Myers Squibb announced that its experimental oral drug, mezigdomide, significantly delayed disease progression in late-stage multiple myeloma ...
Bristol Myers Squibb announced positive Phase 3 trial results for its experimental CELMoD mezigdomide, which significantly delayed disease progression...